Novo Nordisk’s 4.1% Dividend Yield and Accelerating Buyback Set the Stage for a Pivotal FDA Verdict
Published on 06/16/2026 at 14:13 | Redaktion boerse-global.de
Novo Nordisk is sending two clear signals to the market: management thinks the stock is cheap, and the dividend is still growing. The Danish pharma giant has already deployed more than a third of its 15 billion Danish kroner buyback programme, spending roughly 5.27 billion kroner to retire nearly 20 million shares by mid-June. That leaves it holding 0.8% of its own equity. Meanwhile, the dividend yield has swelled to around 4.1% — a level that would have been unthinkable a few years ago when the stock was a pure growth play. The reason for that generous yield is a 15% year-to-date share price decline that has pushed the forward P/E below 10.
Yet the valuation looks doubly intriguing when stacked against the pipeline catalysts expected in the second half of the year. The most consequential is the US Food and Drug Administration’s decision on CagriSema, which is now anticipated in the fourth quarter. New data presented at the ADA congress showed the drug cut the long-term blood sugar marker HbA1c by 1.91 percentage points. An FDA green light would open the door to a US launch as early as the first half of 2027, giving the obesity franchise a second-generation weapon beyond Wegovy.
A further promising candidate, Zenagamtide, is gearing up for Phase 3. In early-stage studies, the highest dose led to an average 14.6% weight loss over 36 weeks, and nearly 89% of participants achieved a clinically relevant blood glucose level. The pivotal trial kicks off in the second half of this year, but investors will have to wait until 2028 for top-line results.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the commercial front, Novo Nordisk notched a significant regulatory win in late May when the UK authorised the Wegovy pill — the first oral semaglutide formulation for obesity to reach a European market. Tablets could lower the barrier for patients reluctant to use weekly injections, potentially expanding the addressable market. In the first quarter of 2026, Wegovy sales rose 12%, while the broader obesity-care division grew 22% on a currency-adjusted basis. Ozempic revenues slipped 8% year-on-year but still beat analyst expectations, and the company plans to roll out more than 20 Ozempic launches globally in 2026.
Despite the positive data flow, Novo Nordisk’s shares remain 43% below their all-time high. The stock recently traded at €38.00, up about 25% from the March low and now comfortably above its 50-day moving average. That technical improvement, combined with a 19-year streak of consecutive dividend increases — the five-year average raise has exceeded 20% annually — and a payout ratio around 50%, gives the equity a dual character as both a recovery play and an income generator. Management has guided for an earnings decline of up to 13% in 2026, but the cushion provided by the buyback and the dividend track record suggests the floor may be firmer than the headline numbers imply. The next trigger is the FDA’s decision on CagriSema, and with it the chance to re-establish Novo Nordisk’s pipeline narrative as the dominant force in metabolic disease.
Ad
Novo Nordisk Stock: New Analysis - 16 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
